Immune Checkpoint Therapy-Induced Lupus Nephritis

Imran Humza Hanif¹, Saifudeen Abdelrahim², Majd Al Shaarani³, Huifang Lu⁴, Raisa Ahmad⁵, Sangeeta Goswami^{5

6

7}, Ala Abudayyeh¹

Affiliations

¹ Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Houston Methodist Hospital, Houston, Texas, USA.
³ Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA.
⁴ Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁵ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁶ Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁷ James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Case Reports

Imran Humza Hanif et al. Kidney Int Rep. 2024.

. 2024 Feb 16;9(5):1534-1537.

doi: 10.1016/j.ekir.2024.02.1396. eCollection 2024 May.

Imran Humza Hanif¹, Saifudeen Abdelrahim², Majd Al Shaarani³, Huifang Lu⁴, Raisa Ahmad⁵, Sangeeta Goswami^{5

6

7}, Ala Abudayyeh¹

¹ Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
² Houston Methodist Hospital, Houston, Texas, USA.
³ Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA.
⁴ Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁵ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁶ Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁷ James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

No abstract available

Figures

1. Toi Y., Sugawara S., Sugisaka J., et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 2019;5:376–383. doi: 10.1001/jamaoncol.2018.5860. - DOI - PMC - PubMed
1. Kitchlu A., Jhaveri K.D., Wadhwani S., et al. A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep. 2021;6:66–77. doi: 10.1016/j.ekir.2020.10.002. - DOI - PMC - PubMed
1. Charkviani M., Herrmann S.M. Immune checkpoint inhibitor-associated sarcoidosis reaction in the kidney: case report. Kidney Med. 2023;5 doi: 10.1016/j.xkme.2023.100626. - DOI - PMC - PubMed
1. Sakakida T., Ishikawa T., Chihara Y., et al. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin Transl Oncol. 2020;22:919–927. doi: 10.1007/s12094-019-02214-8. - DOI - PubMed
1. Barth D.A., Stanzer S., Spiegelberg J., et al. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study. Cancer Med. 2022;11:3074–3083. doi: 10.1002/cam4.4675. - DOI - PMC - PubMed